Logo for Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Investor Relations Material

Latest events

Logo for Pieris Pharmaceuticals Inc

Q1 2023

Pieris Pharmaceuticals
Logo for Pieris Pharmaceuticals

Q2 2023

10 Aug, 2023
Logo for Pieris Pharmaceuticals

Q1 2023

10 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company's pipeline includes PRS-080, a multi-receptor antagonist, which is in Phase II clinical trial for the treatment of dry eye disease, and PRS-094, a transmembrane domain protein receptor antagonist for the treatment of melanoma, colorectal cancer, and multiple myeloma. Pieris Pharmaceuticals was founded in 2009 and is based in Lexington, Massachusetts.